Citations

Clear

75 citation(s) found for "Starlinger, P".

Yield of Staging Laparoscopy for Pancreatic Cancer in the Modern Era: Analysis of More than 1,000 Consecutive Patients
Kendrick, Michael L. , Smoot, Rory L. , Nagorney, David M. , Truty, Mark J. , Gudmundsdottir, Hallbera , Smoot, Rory L , Yonkus, Jennifer A. , Alva‐Ruiz, Roberto , Warner, Susanne G. , Starlinger, Patrick , Thiels, Cornelius A. , Cleary, Sean P. , Grotz, Travis E.

Mayo Clinic

Journal of the American College of Surgeons | April 7, 2023 | Volume: 237 | Issue: 1 | Pages: 49-57

10.1097/xcs.0000000000000704 | PMID 37026837 Get It

BACKGROUND: Accurate staging prior to resection of pancreatic ductal adenocarcinoma (PDAC) is imperative to avoid unnecessary operative morbidity and oncologic futility in patients with occult intra-abdominal distant metastases. We aimed to determine the diagnostic yield of staging laparoscopy (SL) and to identify factors associated with increased risk of positive laparoscopy (PL) in the modern era. STUDY DESIGN: Patients with radiographically localized PDAC who underwent SL from 2017 to 2021 were retrospectively reviewed. The yield of SL was defined as the proportion of patients with PL, including gross metastases and/or positive peritoneal cytology. Factors associated with PL were assessed using univariate analysis and multivariable logistic regression. RESULTS: Of 1,004 patients who underwent SL, 180 (18%) had PL due to gross metastases (n = 140) and/or positive cytology (n = 96). Patients who had neoadjuvant chemotherapy prior to laparoscopy had lower rates of PL (14% vs 22%, p = 0.002). When the analysis was restricted to chemo-naive patients who had concurrent peritoneal lavage performed, 95 of 419 patients (23%) had PL. In multivariable analysis, PL was associated with younger (<60) age, indeterminate extrapancreatic lesions on preoperative imaging, body/tail tumor location, larger tumor size, and elevated serum CA 19-9 (all p < 0.05). Among patients with no indeterminate extrapancreatic lesions on preoperative imaging, the rate of PL ranged from 1.6% in patients with no risk factors to 42% in young patients with large body/tail tumors and elevated serum CA 19-9. CONCLUSIONS: The rate of PL in patients with PDAC remains high in the modern era. SL with peritoneal lavage should be considered for the majority of patients prior to resection, specifically those with high-risk features, and ideally prior to neoadjuvant chemotherapy.
Tyrosine phosphorylation of YAP‐1 in biliary epithelial cells mediates posthepatectomy liver regeneration and is affected by serotonin
Starlinger, Patrick , Brunnthaler, Laura, Watkins, Ryan , Stift, Judith , Santol, Jonas , Assinger, Alice , Smoot, Rory L. , Smoot, Rory L , Assinger, Alice , Starlinger, Patrick , Santol, Jonas , Pereyra, David , Finsterbusch, Michaela , Gruenberger, Thomas

Mayo Clinic

Journal of Cellular Biochemistry | March 22, 2023 | Volume: 124 | Issue: 5 | Pages: 687-700

10.1002/jcb.30398 | PMID 36946436 Get It

AbstractExperimental data suggested activation of yes‐associated protein (YAP‐1) as a critical regulator of liver regeneration (LR). Serotonin (5‐HT) promotes LR in rodent models and has been proposed to act via YAP‐1. How 5‐HT affects LR is incompletely understood. A possible mechanism how 5‐HT affects human LR was explored. Sixty‐one patients were included. Tissue samples prior and 2 h after induction of LR were collected. Circulating levels of 5‐HT and osteopontin (OPN) were assessed. YAP‐1, its phosphorylation states, cytokeratin 19 (CK‐19) and OPN were assessed using immunofluorescence. A mouse model of biliary epithelial cells (BECs) specific deletion of YAP/TAZ was developed. YAP‐1 increased as early as 2 h after induction of LR (p = 0.025) predominantly in BECs. BEC specific deletion of YAP/TAZ reduced LR after 70% partial hepatectomy in mice (Ki67%, p < 0.001). SSRI treatment, depleting intra‐platelet 5‐HT, abolished YAP‐1 and OPN induction upon LR. Portal vein 5‐HT levels correlated with intrahepatic YAP‐1 expression upon LR (R = 0.703, p = 0.035). OPN colocalized with YAP‐1 in BECs and its circulating levels increased in the liver vein 2 h after induction of LR (p = 0.017). In the context of LR tyrosine‐phosphorylated YAP‐1 significantly increased (p = 0.042). Stimulating BECs with 5‐HT resulted in increased YAP‐1 activation via tyrosine‐phosphorylation and subsequently increased OPN expression. BECs YAP‐1 appears to be critical for LR in mice and humans. Our evidence suggests that 5‐HT, at least in part, exerts its pro‐regenerative effects via YAP‐1 tyrosine‐phosphorylation in BECs and subsequent OPN‐dependent paracrine immunomodulation.
Current evidence on posthepatectomy liver failure: comprehensive review
Sparrelid, Ernesto , Dasari, B. , Erdmann, Joris I. , Santol, Jonas , Gilg, Stefan , Dasari, Bobby V M , Erdmann, Joris I , Santol, Jonas , Olthof, Pim , Starlinger, Patrick

Mayo Clinic

BJS Open | November 23, 2022 | Volume: 6 | Issue: 6 | Pages: No page available

10.1093/bjsopen/zrac142 | PMID 36415029 Get It

AbstractIntroductionDespite important advances in many areas of hepatobiliary surgical practice during the past decades, posthepatectomy liver failure (PHLF) still represents an important clinical challenge for the hepatobiliary surgeon. The aim of this review is to present the current body of evidence regarding different aspects of PHLF.MethodsA literature review was conducted to identify relevant articles for each topic of PHLF covered in this review. The literature search was performed using Medical Subject Heading terms on PubMed for articles on PHLF in English until May 2022.ResultsUniform reporting on PHLF is lacking due to the use of various definitions in the literature. There is no consensus on optimal preoperative assessment before major hepatectomy to avoid PHLF, although many try to estimate future liver remnant function. Once PHLF occurs, there is still no effective treatment, except liver transplantation, where the reported experience is limited.DiscussionStrict adherence to one definition is advised when reporting data on PHLF. The use of the International Study Group of Liver Surgery criteria of PHLF is recommended. There is still no widespread established method for future liver remnant function assessment. Liver transplantation is currently the only effective way to treat severe, intractable PHLF, but for many indications, this treatment is not available in most countries.
SHP2 inhibition enhances Yes-associated protein–mediated liver regeneration in murine partial hepatectomy models
Watkins, Ryan , Buckarma, EeeLN H. , Tomlinson, Jennifer L. , McCabe, Chantal E. , Yonkus, Jennifer A. , Werneburg, Nathan W., Bayer, Rachel L., Starlinger, Patrick , Robertson, Keith D. , Wang, Chen , Smoot, Rory L. , Smoot, Rory L , Robertson, Keith D , Wang, Chen , Starlinger, Patrick , Yonkus, Jennifer A , Buckarma, EeeLN , Tomlinson, Jennifer , Gores, Gregory J.

Mayo Clinic

JCI Insight | June 28, 2022 | Volume: 7 | Issue: 15 | Pages: No page available

10.1172/jci.insight.159930 | PMID 35763355 Get It

Disrupted liver regeneration following hepatectomy represents an “undruggable” clinical challenge associated with poor patient outcomes. Yes-associated protein (YAP), a transcriptional coactivator that is repressed by the Hippo pathway, is instrumental in liver regeneration. We have previously described an alternative, Hippo-independent mechanism of YAP activation mediated by downregulation of protein tyrosine phosphatase nonreceptor type 11 (PTPN11, also known as SHP2) inhibition. Herein, we examined the effects of YAP activation with a selective SHP1/SHP2 inhibitor, NSC-87877, on liver regeneration in murine partial hepatectomy models. In our studies, NSC-87877 led to accelerated hepatocyte proliferation, improved liver regeneration, and decreased markers of injury following partial hepatectomy. The effects of NSC-87877 were lost in mice with hepatocyte-specific Yap/Taz deletion, and this demonstrated dependence on these molecules for the enhanced regenerative response. Furthermore, administration of NSC-87877 to murine models of nonalcoholic steatohepatitis was associated with improved survival and decreased markers of injury after hepatectomy. Evaluation of transcriptomic changes in the context of NSC-87877 administration revealed reduction in fibrotic signaling and augmentation of cell cycle signaling. Cytoprotective changes included downregulation of Nr4a1 , an apoptosis inducer. Collectively, the data suggest that SHP2 inhibition induces a pro-proliferative and cytoprotective enhancement of liver regeneration dependent on YAP.
Immunological Aspects of AXL/GAS‐6 in the Context of Human Liver Regeneration
Ortmayr, Gregor , Brunnthaler, Laura, Huber, Heidemarie, Santol, Jonas , Rumpf, Benedikt , Najarnia, S. , Smoot, Rory L. , Ammon, Daphni , Sorz, Thomas , Fritsch, Fabian, Schodl, Michael, Voill‐Glaninger, Astrid , Weitmayr, Barbara, Födinger, Manuela, Klimpfinger, M., Assinger, Alice , Pereyra, David , Starlinger, Patrick , Smoot, Rory L , Assinger, Alice , Santol, Jonas , Pereyra, David , Gruenberger, Thomas , Mikulits, Wolfgang , Starlinger, Patrick

Mayo Clinic

Hepatology Communications | December 24, 2021 | Volume: 6 | Issue: 3 | Pages: 576-592

10.1002/hep4.1832 | PMID 34951136 Get It

AXL and its corresponding ligand growth arrest–specific 6 (GAS‐6) are critically involved in hepatic immunomodulation and regenerative processes. Pleiotropic inhibitory effects on innate inflammatory responses might essentially involve the shift of macrophage phenotype from a pro‐inflammatory M1 to an anti‐inflammatory M2. We aimed to assess the relevance of the AXL/GAS‐6‐pathway in human liver regeneration and, consequently, its association with clinical outcome after hepatic resection. Soluble AXL (sAXL) and GAS‐6 levels were analyzed at preoperative and postoperative stages in 154 patients undergoing partial hepatectomy and correlated with clinical outcome. Perioperative dynamics of interleukin (IL)‐6, soluble tyrosine‐protein kinase MER (sMerTK), soluble CD163 (sCD163), and cytokeratin (CK) 18 were assessed to reflect pathophysiological processes. Preoperatively elevated sAXL and GAS‐6 levels predicted postoperative liver dysfunction (area under the curve = 0.721 and 0.722; P < 0.005) and worse clinical outcome. These patients failed to respond with an immediate increase of sAXL and GAS‐6 upon induction of liver regeneration. Abolished AXL pathway response resulted in a restricted increase of sCD163, suggesting a disrupted phenotypical switch to regeneratory M2 macrophages. No association with sMerTK was observed. Concomitantly, a distinct association of IL‐6 levels with an absent increase of AXL/GAS‐6 signaling indicated pronounced postoperative inflammation. This was further supported by increased intrahepatic secondary necrosis as reflected by CK18M65. sAXL and GAS‐6 represent not only potent and easily accessible preoperative biomarkers for the postoperative outcome but also AXL/GAS‐6 signaling might be of critical relevance in human liver regeneration. Refractory AXL/GAS‐6 signaling, due to chronic overactivation/stimulation in the context of underlying liver disease, appears to abolish their immediate release following induction of liver regeneration, causing overwhelming immune activation, presumably via intrahepatic immune regulation.
Risk of de novo severe carpal tunnel syndrome after bilateral oophorectomy: a population-based cohort study
Schrier, Verena J.M.M. , Song, Joanne, Rocca, Liliana Gazzuola , Amadio, Peter C. , Rocca, Walter A. , Starlinger, Julia , Gazzuola Rocca, Liliana, Smith, Carin Y. , Stewart, Elizabeth A.

Mayo Clinic

Menopause | May 25, 2021 | Volume: 28 | Issue: 9 | Pages: 1026-1036

10.1097/gme.0000000000001804 | PMID 34033605 Get It

Abstract Objective: The incidence of carpal tunnel syndrome (CTS) is higher in women, and peaks around the age of menopause. Therefore, we investigated whether bilateral oophorectomy is associated with an increased risk of severe CTS. Methods: We included all of the 1,653 premenopausal women who underwent bilateral oophorectomy for a nonmalignant indication between 1988 and 2007, and a random sample of 1,653 age-matched referent women who did not undergo bilateral oophorectomy in Olmsted County, MN. Diagnoses of CTS assigned to women over their entire lifetime were identified in these two cohorts. The risk of de novo severe CTS after bilateral oophorectomy (or index date) was evaluated using Cox proportional hazards models adjusted for potential confounders. Results: Bilateral oophorectomy was associated with an increased risk of severe CTS (adjusted hazard ratio 1.65, 95% confidence interval 1.20-2.25). The risk was suggestively greater in women with lower body mass index, nulliparity, and with a benign ovarian indication for oophorectomy (nonsignificant interactions). We did not observe a protective effect of estrogen therapy after the oophorectomy. The findings were similar in secondary analyses considering the incidence of CTS of any severity or idiopathic CTS. Conclusions: The risk of severe CTS, common in perimenopausal women, is increased after bilateral oophorectomy. The association may be causal or due to confounding. Therefore, the precise biological mechanisms explaining the association and the absence of a mitigating effect of estrogen therapy should be further investigated.
The Addition of C‐Reactive Protein and von Willebrand Factor to Model for End‐Stage Liver Disease‐Sodium Improves Prediction of Waitlist Mortality
Starlinger, Patrick , Ahn, Joseph , Gyöeri, Georg , Pereyra, David , Alva‐Ruiz, Roberto, Hackl, Hubert , Reiberger, Thomas , Trauner, Michael , Santol, Jonas , Simbrunner, Benedikt , Mandorfer, Mattias , Kamath, Patrick S. , Mullan, Aidan, Gyoeri, Georg P , Pereyra, David , Alva-Ruiz, Roberto, Reiberger, Thomas , Mandorfer, Mattias , Ahn, Joseph C , Starlinger, Patrick , Hackl, Hubert , Santol, Jonas , Mullan, Aidan F. , Györi, Georg, Berlakovich, Gabriela , Heimbach, Julie K.

Mayo Clinic

Hepatology | March 31, 2021 | Volume: 74 | Issue: 3 | Pages: 1533-1545

10.1002/hep.31838 | PMID 33786862 Get It

Background and Aims Patients with cirrhosis on the liver transplant (LT) waiting list may die or be removed because of complications of portal hypertension (PH) or infections. von Willebrand factor antigen (vWF‐Ag) and C‐reactive protein (CRP) are simple, broadly available markers of these processes. Approach and Results We determined whether addition of vWF‐Ag and CRP to the Model for End‐Stage Liver Disease‐Sodium (MELD‐Na) score improves risk stratification of patients awaiting LT. CRP and vWF‐Ag at LT listing were assessed in two independent cohorts (Medical University of Vienna [exploration cohort] and Mayo Clinic Rochester [validation cohort]). Clinical characteristics, MELD‐Na, and mortality on the waiting list were recorded. Prediction of 3‐month waiting list mortality was assessed by receiver operating characteristics curve (ROC‐AUC). In order to explore potential mechanisms underlying the prognostic utility of vWF‐Ag and CRP in this setting, we evaluated their association with PH, bacterial translocation, systemic inflammation, and circulatory dysfunction. In the exploration cohort (n = 269) vWF‐Ag and CRP both improved the predictive value of MELD‐Na for 3‐month waitlist mortality and showed the highest predictive value when combined (AUC: MELD‐Na, 0.764; MELD‐Na + CRP, 0.790; MELD‐Na + vWF, 0.803; MELD‐Na + CRP + vWF‐Ag, 0.824). Results were confirmed in an independent validation cohort (n = 129; AUC: MELD‐Na, 0.677; MELD‐Na + CRP + vWF‐Ag, 0.882). vWF‐Ag was independently associated with PH and inflammatory biomarkers, whereas CRP closely, and MELD independently, correlated with biomarkers of bacterial translocation/inflammation. Conclusions The addition of vWF‐Ag and CRP—reflecting central pathophysiological mechanisms of PH, bacterial translocation, and inflammation, that are all drivers of mortality on the waiting list for LT—to the MELD‐Na score improves prediction of waitlist mortality. Using the vWFAg‐CRP‐MELD‐Na model for prioritizing organ allocation may improve prediction of waitlist mortality and decrease waitlist mortality.
Till Death Do Us Part—The Multifaceted Role of Platelets in Liver Diseases
Mußbacher, Marion , Brunnthaler, Laura, Panhuber, Anja, Assinger, Alice , Assinger, Alice , Starlinger, Patrick

Mayo Clinic

International Journal of Molecular Sciences | March 18, 2021 | Volume: 22 | Issue: 6 | Pages: 3113

10.3390/ijms22063113 | PMID 33803718 Get It

Platelets are tightly connected with the liver, as both their production and their clearance are mediated by the liver. Platelets, in return, participate in a variety of liver diseases, ranging from non-alcoholic fatty liver diseases, (viral) hepatitis, liver fibrosis and hepatocellular carcinoma to liver regeneration. Due to their versatile functions, which include (1) regulation of hemostasis, (2) fine-tuning of immune responses and (3) release of growth factors and cellular mediators, platelets quickly adapt to environmental changes and modulate disease development, leading to different layers of complexity. Depending on the (patho)physiological context, platelets exert both beneficial and detrimental functions. Understanding the precise mechanisms through which platelet function is regulated at different stages of liver diseases and how platelets interact with various resident and non-resident liver cells helps to draw a clear picture of platelet-related therapeutic interventions. Therefore, this review summarizes the current knowledge on platelets in acute and chronic liver diseases and aims to shed light on how the smallest cells in the circulatory system account for changes in the (patho)physiology of the second largest organ in the human body.
Combined APRI/ALBI score to predict mortality after hepatic resection
Starlinger, Patrick , Ubl, Daniel S. , Hackl, Hubert , Starlinger, Johannes , Nagorney, David M. , Smoot, Rory L. , Habermann, Elizabeth B. , Smoot, Rory L , Habermann, Elizabeth , Starlinger, Patrick , Hackl, Hubert , Cleary, Sean P.

Mayo Clinic

BJS Open | January 17, 2021 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/bjsopen/zraa043 | PMID 33609383 Get It

Abstract Background Aspartate aminotransferase/platelet ratio index (APRI) and albumin–bilirubin grade (ALBI) are validated prognostic indices implicated as predictors of postoperative liver dysfunction after hepatic resection. The aim of this study was to evaluate the relevance of the combined APRI/ALBI score for postoperative clinically meaningful outcomes. Methods Patients undergoing hepatectomy were included from the American College of Surgeons National Surgical Quality Improvement Program database. The association between APRI/ALBI score and postoperative grade C liver dysfunction, liver dysfunction-associated and overall 30-day mortality was assessed. Results A total of 12 055 patients undergoing hepatic resection from 2014 to 2017 with preoperative blood values and detailed 30-day postoperative outcomes were included (exploration cohort: January 2014 to December 2016; validation cohort: 2017). In the exploration cohort (8538 patients), the combination of both scores (APRI/ALBI) was significantly associated with postoperative grade C liver dysfunction, 30-day mortality, and liver dysfunction-associated 30-day mortality, and was superior to either score alone. The association with postoperative 30-day mortality was confirmed in multivariable analysis. A predictive model was generated using the exploration cohort. The predicted incidence of events closely followed the observed incidence in the validation cohort (3517 patients). Subgroup analyses of tumour types were used to generate disease-specific risk models to assess risk in different clinical scenarios. These findings informed development of a smartphone application (https://tellaprialbi.37binary.com). Conclusion The predictive potential of the combined APRI/ALBI score for clinically relevant outcomes such as mortality was demonstrated. An evidence-based smartphone application will allow clinical translation and facilitation of risk assessment before hepatic resection using routine laboratory parameters.